Pricing Log in Create free account
Saturday 17 October 2026 Export RXST’s income statement to Excel — free account

RxSight, Inc.

RXST Healthcare Medical Devices

RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

4.51 0.16 −3.43%
Market cap
$194.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
5.03
Beneish M
−3.15
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — 4 —
Insider Ownership 7.02%

Capital & Financial Ratios $m

Market Cap 194.24
Revenue 127.58
Net Income (46.95)
Free Cash Flow (27.16)
Net Debt (208.80)
Current Ratio 4.07 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.53) (negative: loss-making)
P/S ratio 1.47
P/B ratio 0.71
Past 5Y EPS Growth —
This Y EPS Growth 0.66%
Next Y EPS Growth (23.42%) (below 0%: weak)
Next Y revenue growth 9.39%
Next 5Y EPS Growth 10.81%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.0×, against a ten-year median of 6.6×; over the ten years it ranged from 0.0× in 2026 to 20.9× in 2024.
P/S against its own 10 years 0.08%
10-year low 10-year high
P/B against its own 10 years 0.16%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 127 237 228 209
Receivables 20 30 23 79
Inventory 17 22 32 37
Other — — — —
168 294 287 327
2023 2024 2025 Q'26
Payables 4 5 5 6
ST’ Debt — — — —
Other — — — 50
21 26 26 80

Compound Annual Growth %

10y 5y 3y
Sales — 55.74% 40.00%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 152.50% 45.28%

Revenue $m

Mar Jun Sep Dec Year
’26 31 34 — — —
’25 38 34 30 33 134
’24 30 35 35 40 140
’23 17 21 22 29 89
’22 9 11 13 16 49
’21 3 5 6 8 23
’20 — 3 4 — 15
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (10) — — —
’25 (9) (4) (1) (1) (16)
’24 (9) (4) 1 (4) (17)
’23 (18) (8) (8) (8) (42)
’22 (15) (15) (15) (14) (59)
’21 (10) (12) (14) (9) (45)
’20 — (20) (7) (8) (35)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (11) — — —
’25 (9) (6) (2) (2) (19)
’24 (11) (6) 0 (5) (22)
’23 (19) (9) (9) (10) (46)
’22 (15) (16) (16) (14) (61)
’21 (11) (13) (14) (9) (47)
’20 — (21) (8) (9) (38)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.38) (0.29) — — —
’25 (0.20) (0.29) (0.24) (0.22) (0.95)
’24 (0.25) (0.16) (0.16) (0.15) (0.71)
’23 (0.42) (0.40) (0.35) (0.26) (1.41)
’22 (0.64) (0.61) (0.61) (0.56) (2.41)
’21 (1.70) (3.53) (0.68) (0.58) (3.57)
’20 — — — — 4.98
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 9.18 8.80 12.06 33.03 6.32

Analyst estimates 2026–2028

Powerpack
High — — — — — 19.67 16.99 41.43 66.54 37.13
People
People Employees — — — — 171 221 292 374 498 461
Revenue/emp, $m — — — 0.00 0.09 0.10 0.17 0.24 0.28 0.29
Income, $m
Income, $m Revenue — — — 2 15 23 49 89 140 134
Gross margin, % — — — (81.17) 11.62 19.99 43.52 60.36 70.71 76.60
EBT — — — 126 28 (49) (67) (49) (27) (39)
EBT margin, % — — — 5,633.38 188.25 (215.46) (136.20) (54.55) (19.59) (28.91)
Net income — 0 — 108 28 (49) (67) (49) (27) (39)
Depreciation — — — 4 4 4 3 (2) (5) (5)
Per share, $
Per share, $ Revenue — — — 0.08 3.96 1.66 1.77 2.59 3.60 3.29
Earnings — — — 0.95 7.44 (3.57) (2.41) (1.41) (0.71) (0.95)
Cash flow — — — (1.47) (9.50) (3.28) (2.13) (1.21) (0.44) (0.38)
Capex — — — 0.00 (0.68) (0.14) (0.09) (0.14) (0.14) (0.09)
Free cash flow — — — (1.47) (10.18) (3.42) (2.21) (1.35) (0.58) (0.47)
Book value — — — 0.83 0.72 10.15 3.25 4.65 7.24 6.75
Shares, m — — — 28 4 14 28 34 39 41
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 4.31 4.31 6.78 7.21 14.18 9.55 3.17
P/B — — — 0.00 0.00 1.11 3.93 7.87 4.75 1.54
EV/Sales — — — 2.85 2.85 1.49 5.87 12.97 7.99 1.61
EV/FCF — — — (1.09) (1.09) (0.72) (4.70) (24.89) (49.97) (11.23)
Cash, $m
Cash, $m Operating cash flow — — — (41) (35) (45) (59) (42) (17) (16)
Capex — — — (4) (3) (2) (2) (5) (5) (4)
Free cash flow — — — (41) (38) (47) (61) (46) (22) (19)
Balance, $m
Balance, $m Working capital — — — 82 70 165 117 148 268 261
Total debt — — — 6 24 40 40 — — —
Net debt — — — (75) (45) (120) (66) (127) (237) (228)
Shareholders’ equity — — — 23 3 138 90 160 281 276
Returns, %
Returns, % ROA — — — 47.32 3.19 (33.19) (38.94) (29.22) (10.96) (12.36)
ROIC — — — 0.00 0.00 (176.71) (163.06) (94.34) (52.34) (63.34)
ROE — — — 0.00 (1.03) 45.85 (58.52) (38.85) (12.43) (13.99)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

RxSight, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CATX Perspective Therapeutics, Inc. $267.1M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%) Compare
LAB Standard BioTools Inc. $258.5M 2.9× — (loss-making) −7.62% (below 0%: shrinking) n/m +52.76% (above 0%: growing) 52.40% (126.28%) Compare
TLSI TriSalus Life Sciences, Inc. $240.1M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
ELMD Electromed, Inc. $232.3M 20.0× 25.5× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70% Compare
PROF Profound Medical $230.5M — (loss-making) — (loss-making) +12.30% (above 0%: growing) n/m +17.51% (above 0%: growing) 78.41% (445.67%) Compare
RXST RxSight, Inc. $194.2M — (loss-making) — (loss-making) +0.31% (above 0%: growing) n/m −94.39% (below 0%: shrinking) 76.72% (40.81%)
INGN Inogen, Inc $167.1M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
STIM Neuronetics, Inc. $148.6M — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +62.06% (above 0%: growing) 51.06% (3.61%) Compare
QTRX Quanterix Corporation $145.2M — (loss-making) — (loss-making) +34.44% (above 0%: growing) n/m +18.92% (above 0%: growing) 38.52% (150.22%) Compare
Median of peers $231.4M — — +6.06% — −3.82% 65.41% (106.15%)

All 149 Medical Devices stocks →

RxSight, Inc. (RXST) key facts

  • Concern: RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
  • RxSight, Inc. (RXST) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, RXST traded at $4.51, a market capitalization of $194.2 million.
  • Return on equity was −14.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 5.03 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

RxSight, Inc. (RXST) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RXST · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com